11 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $68M | -$413M | 0.0% | -651.7% | -$396M | — | $155M |
| 2024 | $58M | -$519M | 0.0% | -923.1% | -$355M | — | $189M |
| 2023 | $36M | -$481M | 0.0% | -1420.5% | -$408M | — | $227M |
| 2022 | $52M | -$474M | 0.0% | -879.0% | -$347M | — | $524M |
| 2021 | $33M | -$268M | 100.0% | -810.4% | -$238M | — | $123M |
| 2020 | $58M | -$134M | 100.0% | -235.5% | -$53M | — | $160M |
| 2019 | $43M | -$474M | 100.0% | -246.8% | -$110M | — | $57M |
| 2018 | $30M | -$85M | 100.0% | -298.6% | -$68M | — | $59M |
| 2017 | $26M | -$68M | 0.0% | -266.3% | -$75M | — | $341M |
| 2016 | $16M | -$32M | 0.0% | -195.2% | $30M | — | $273M |
| 2015 | — | -$12M | — | — | — | — | $76M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $15M | -$96M | 0.0% | -668.1% | -$117M | — | $135M |
| Dec '25 | $23M | -$96M | 0.0% | -428.9% | -$69M | — | $155M |
| Sep '25 | $14M | -$101M | 0.0% | -808.9% | -$77M | — | $193M |
| Jun '25 | $14M | -$101M | 0.0% | -772.2% | -$100M | — | $156M |
| Mar '25 | $17M | -$114M | 0.0% | -726.6% | -$150M | — | $127M |
| Dec '24 | $13M | -$129M | 0.0% | -1059.9% | -$86M | — | $189M |
| Sep '24 | $9M | -$136M | 0.0% | -1589.0% | -$86M | — | $120M |
| Jun '24 | $7M | -$147M | 0.0% | -1998.6% | -$59M | — | $131M |
| Mar '24 | $29M | -$107M | 0.0% | -394.0% | -$123M | — | $172M |
| Dec '23 | -$2M | -$132M | 0.0% | 7297.4% | -$95M | — | $227M |
| Sep '23 | $12M | -$122M | 0.0% | -1093.3% | -$106M | — | $168M |
| Jun '23 | $14M | -$124M | 0.0% | -973.5% | -$95M | — | $172M |
| Mar '23 | $13M | -$103M | 0.0% | -888.1% | -$113M | — | $294M |
| Dec '22 | $14M | -$113M | 0.0% | -811.1% | -$94M | — | $524M |
| Sep '22 | $13M | -$113M | 0.0% | -795.5% | -$83M | — | $141M |
| Jun '22 | $14M | -$101M | 0.0% | -700.6% | -$89M | — | $148M |
| Mar '22 | $11M | -$147M | 0.0% | -1282.0% | -$81M | — | $133M |
| Dec '21 | $13M | -$81M | 0.0% | -625.6% | -$58M | — | $123M |
| Sep '21 | $7M | -$72M | 0.0% | -999.3% | -$70M | — | $335M |
| Jun '21 | $7M | -$69M | 0.0% | -1053.7% | -$56M | — | $130M |
How the market has priced NTLA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Intellia Therapeutics, Inc.'s revenue has grown 3.1% per year. These are computed facts, not advice.
As of FY2025, Intellia Therapeutics, Inc. reported — of total debt against $155M of cash.
In FY2025, gross margin was —, operating margin -651.7%, and net margin -609.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.